HealthTronics, Inc. (Nasdaq:HTRN), a leading provider of Urology
services and products, today announced its financial results for
the quarter ended December 31, 2009.
Fourth Quarter 2009
Revenue from continuing operations for the fourth quarter of
2009 totaled $50.3 million, up from $44.6 million in the fourth
quarter of 2008. The Company's net loss for the fourth quarter of
2009, in accordance with generally accepted accounting principles
("GAAP"), totaled $2.3 million or $0.05 per diluted share. The
Company's non-GAAP net income, which excludes stock based
compensation and certain costs related primarily to the Endocare
transaction, totaled $0.06 per share in the quarter. This
compares to non-GAAP net income of $0.03 per share in the fourth
quarter of 2008.
The Company's Adjusted EBITDA from continuing operations for the
fourth quarter of 2009 was $8.5 million, which compares to $5.8
million in the fourth quarter of 2008. In addition, After Tax
Cash Flow (cash flow from operations less distributions to
non-controlling interests) excluding acquisition related costs was
$5.0 million for the fourth quarter of 2009.
Full Year 2009
Revenue from continuing operations for the year ended December
31, 2009 totaled $185.3 million as compared to $165.9 million for
the year ended December 31, 2008. The Company's loss from
continuing operations in 2009, in accordance with GAAP, totaled
$3.9 million or $0.10 per share on a diluted basis. The Company's
2009 non-GAAP net income, which excludes stock based compensation
and certain costs related primarily to the Endocare transaction,
totaled $0.16 per share. The Company's Adjusted EBITDA from
continuing operations for 2009 was $26.6 million compared to $22.0
million in 2008.
Endocare Results
After excluding one-time transaction costs, the acquisition of
Endocare contributed $2.9 million in EBITDA in the fourth
quarter. Revenue contributed by Endocare after intercompany
eliminations totaled $4.7 million and, before eliminating
intercompany sales, totaled $7.1 million for the quarter.
Executive Commentary
James Whittenburg, President and Chief Executive Officer,
commented, "Our Fourth Quarter and Year-End results mark excellent
progress in our ability to successfully leverage our platform of
unique relationships with over 2,500 urologists nationally. We
continue to gain greater traction in our mission to improve both
patient care and physician practice economics through delivering
exceptional products and services in urology. In 2006, roughly
three-fourths of our urology revenue derived from
lithotripsy. Since that time we have aggressively expanded our
scope of products and services, which now include uropathology,
radiation therapy for prostate and other cancers, cryotherapy for
prostate, renal and other cancers, laser treatment for benign
prostate enlargement, and a robust devices, maintenance and
consumables business.
Our guidance for 2010 reflects a more diversified business, with
non-lithotripsy revenues accounting for roughly 50% of our total
revenues. Importantly, our lithotripsy revenues have grown
during the same timeframe.
We believe our progress in fulfilling our mission yields a
compounding effect. Our success in creating value for our
physician partners in turn creates success in growing the size of
our channel. A more robust channel in turn creates even more
compelling business opportunities that yield value for our
shareholders. Endocare, with its strong strategic and
financial contribution, is but the latest achievement that
highlights the true intrinsic value of our highly unique role in
urology.
As we move forward in 2010 and beyond, we believe, more than
ever, that we possess a rare combination of strong urologist
relationships, national scope and scale, and demonstrated ability
to creatively identify new products and services that foster
growth. We will strive to build on our current momentum to
create additional value through organic growth and a disciplined
approach to strategic acquisitions."
Guidance for Full Year 2010
The Company provides the following financial guidance for full
year 2010, excluding one-time costs related to the Endocare
acquisition:
Consolidated revenue of $203 to $208 million
Positive Adjusted EBITDA contribution of $32 to $34 million
After Tax Cash Flow of $20 to 22 million
Earnings per share of $0.25 to $0.30
The Company's 2010 guidance reflects continued reinvestment into
growth initiatives that help position the Company for meaningful
organic growth in 2011 and beyond. Full year guidance does not
reflect historical quarterly seasonality in the Company's base
lithotripsy business, which historically shows procedure volume
increasing quarter over quarter in the second and third quarters
and then tapering in the fourth quarter. The guidance does not
reflect contribution from any acquisitions that may take place
during 2010.
Conference Call and Webcast: Management of HealthTronics will
host a conference call the afternoon of Thursday, March 4, 2010 at
5:00 pm EST. Interested parties may participate in the call by
dialing 1-877-723-9521 (international callers dial 1-719-325-4942)
and ask for the "HealthTronics Q4 2009 Earnings Call" (conference
ID: 5641068). Please call in 10 minutes before the call is
scheduled to begin. The conference call will also be webcast live
via the Investors section of HealthTronics' website at
www.healthtronics.com. To listen to the live webcast, go to the
website at least 10 minutes early to register, download and install
any necessary audio software. If you are unable to listen live, the
conference call will be archived on the HealthTronics website.
About HealthTronics, Inc.: HealthTronics is a premier urology
company providing an exclusive suite of healthcare services and
technology, including urologist partnership opportunities, surgical
and capital equipment, maintenance services offerings, and
anatomical pathology services. For more information, visit
www.healthtronics.com.
The HealthTronics, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5894
HealthTronics' use of Non GAAP Financial Measures:
This press release includes financial measures for net income
(loss), net income (loss) from continuing operations, and related
per share amounts that exclude certain charges and therefore have
not been calculated in accordance with U.S. generally accepted
accounting principles (GAAP). These non-GAAP financial measures may
be different from non-GAAP financial measures used by other
companies. Non-GAAP financial measures should not be considered as
a substitute for, or superior to, measures of financial performance
prepared in accordance with GAAP. By excluding certain charges,
these non-GAAP financial measures facilitate management's internal
comparisons to the Company's historical operating results, to
competitors' operating results, and to estimates made by securities
analysts. Management uses these non-GAAP financial measures
internally to evaluate its performance. The Company believes these
non-GAAP financial measures are useful to decision-making. In
addition, the Company has historically reported similar non-GAAP
financial measures to its investors and believes that the inclusion
of comparative numbers provides consistency in its financial
reporting. Investors are encouraged to review the reconciliation of
the non-GAAP financial measures used in this press release to their
most directly comparable GAAP financial measure as provided in the
financial statements attached to this press release.
After Tax Cash Flow: HealthTronics has presented After Tax Cash
Flow, a non-GAAP financial measure. HealthTronics believes its
presentation of After Tax Cash Flow is an important supplemental
measure of its operating performance to its investors.
After Tax Cash Flow is intended to give investors a clear
picture of the cash being generated by HealthTronics at the
corporate level. After Tax Cash Flow is calculated using Net
Cash Provided by Operating Activities and subtracting Distributions
to Non-controlling Interests. HealthTronics believes that
After Tax Cash Flow highlights the value of the Company's tax
assets as well as other benefits beyond those reflected in the
Company's GAAP Net Income. For example, After Tax Cash Flow
includes the impact of changes in working capital and thereby
provides better insight into the Company's ability to manage
payables, receivables and inventory.
To convert from After Tax Cash Flow to what is typically
referred to as Free Cash Flow, one would subtract capital
expenditures made at the corporate level. It is important to
note that the "Purchases of equipment and leasehold improvements"
reflected on the Company's cash flow statements includes capital
expenditures at both the corporate and partnership level and a
significant portion of expenditures are made in equipment at the
partnerships. Thus, a break out of capital expenditures at
the corporate and physician partnership level is included
herein.
Prior to 2009, distributions to our partners were made on an
irregular quarterly basis that was based on the tax calendar.
We now make distributions on a monthly basis. At the time we
made the switch, we anticipated the investor community would
benefit from the increased transparency into operating cash
flows. Thus, by highlighting After Tax Cash Flow in our
quarterly releases, HealthTronics will be leveraging this increased
transparency. However, it is important to note that given the
irregular distribution schedule in prior years, HealthTronics will
not be able to make year-over-year comparisons until the second
quarter of 2010.
EBITDA and Adjusted EBITDA: HealthTronics has presented EBITDA
and Adjusted EBITDA amounts, which are non-GAAP financial measures.
In the financial statements attached to this press release,
HealthTronics has reconciled such amounts to their most directly
comparable financial measure calculated in accordance with GAAP,
which is HealthTronics' net income. HealthTronics believes that its
presentations of EBITDA and Adjusted EBITDA are useful supplemental
measures of operating performance to its investors.
Earnings before interest, taxes, depreciation and amortization
("EBITDA") is a commonly used measure of performance which
HealthTronics believes, when considered with measures calculated in
accordance with GAAP, gives investors a more complete understanding
of HealthTronics' operating results before the impact of investing
and financing transactions and income taxes. HealthTronics does not
subtract noncontrolling interest expense when calculating EBITDA;
however, HealthTronics does adjust for noncontrolling interest
expense and refers to this measure as "Adjusted EBITDA." "Adjusted
EBITDA" also excludes stock-based compensation
expense. Noncontrolling interest is a GAAP measure intended to
reflect our partner's share of our consolidated net income and not
our partner's share of our consolidated EBITDA. For example,
calculation of noncontrolling interest expense does not include
adjustments for depreciation, amortization, taxes or interest. As a
result, our partners' share of consolidated EBITDA may not, in a
given reporting period, equal the deduction for noncontrolling
interest expense used in arriving at Adjusted EBITDA. HealthTronics
has historically reported Adjusted EBITDA to its investors and
believes that the continued inclusion of Adjusted EBITDA provides
consistency in its financial reporting. Adjusted EBITDA is used in
management's internal evaluation of total company performance.
Adjusted EBITDA is also used by HealthTronics management in the
annual budgeting process. HealthTronics believes these measures
continue to be used by investors and creditors in their assessment
of HealthTronics' operational performance and the valuation of the
company.
EBITDA and Adjusted EBITDA are used in addition to and in
conjunction with results presented in accordance with GAAP. EBITDA
and Adjusted EBITDA should not be considered as an alternative to
net income, operating income, a liquidity measure, or any other
operating performance measure prescribed by GAAP, nor should these
measures be relied upon to the exclusion of GAAP financial
measures. EBITDA and Adjusted EBITDA reflect additional ways of
viewing HealthTronics' operations that HealthTronics believes, when
viewed with its GAAP results and the reconciliations to the
corresponding GAAP financial measures, provide a more complete
understanding of factors and trends affecting HealthTronics'
business than could be obtained absent this disclosure.
Cautionary Language: Statements by the Company's management made
in this press release that are not strictly historical, including
statements regarding plans, objective and future financial
performance, are "forward-looking" statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Although HealthTronics believes that
the expectations reflected in such forward-looking statements are
reasonable, no assurance can be given that the expectations will
prove to be correct. Factors that could cause actual results to
differ materially from HealthTronics' expectations include, among
others, the existence of demand for and acceptance of
HealthTronics' services, regulatory approvals, economic conditions,
the impact of competition and pricing, the availability and terms
of financing and other factors described from time to time in
HealthTronics' periodic filings with the Securities and Exchange
Commission.
HEALTHTRONICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
($ in thousands, except per share data)
Three Months Ended
December 31,
Year Ended
December 31,
2009
2008
2009
2008
Revenues
$ 50,279
$ 44,637
$ 185,330
$ 165,942
Cost of revenues (exclusive of depreciation and amortization
shown separately below)
25,645
21,422
90,660
75,679
Gross profit
24,634
23,215
94,670
90,263
Operating expenses:
Selling, general and administrative
7,340
5,820
24,046
20,006
Impairment charges
--
144,000
--
144,000
Depreciation and amortization
3,931
3,593
14,544
12,363
Total operating expenses
11,271
153,413
38,590
176,369
Operating income
13,363
(130,198)
56,080
(86,106)
Other income (expenses):
Interest and dividends
6
135
101
1,233
Interest expense
(689)
(486)
(1,576)
(1,077)
(683)
(351)
(1,475)
156
Income (loss) from operations before provision for income
taxes
12,680
(130,549)
54,605
(85,950)
Provision for income taxes
870
(13,246)
2,837
(11,516)
Consolidated net income (loss)
11,810
(117,303)
51,768
(74,434)
Less: Net income attributable to noncontrolling
interest
(14,143)
(13,879)
(55,684)
(54,259)
Net loss attributable to HealthTronics, Inc.
$ (2,333)
$ (131,182)
$ (3,916)
$ (128,693)
Basic earnings per share attributable to HealthTronics,
Inc.:
Net loss attributable to HealthTronics, Inc.
$ (0.05)
$ (3.64)
$ (0.10)
$ (3.53)
Weighted average shares outstanding
43,491
36,004
39,135
36,499
Diluted earnings per share attributable to HealthTronics,
Inc.:
Net loss attributable to HealthTronics, Inc.
$ (0.05)
$ (3.64)
$ (0.10)
$ (3.53)
Weighted average shares outstanding
43,491
36,004
39,135
36,499
HealthTronics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
($ in thousands)
December 31,
2009
December 31,
2008
ASSETS
Total current assets
$ 58,003
$ 63,689
Property and equipment, net
32,881
32,769
Goodwill
103,282
93,620
Other assets
54,953
44,308
$ 249,119
$ 234,386
LIABILITIES
Total current liabilities
$ 20,365
$ 18,274
Long-term debt, net of current portion
45,963
43,897
Other long-term liabilities
9,375
5,120
Total liabilities
75,703
67,291
Total HealthTronics, Inc. shareholders' equity
130,390
119,372
Noncontrolling interest
43,026
47,723
$ 249,119
$ 234,386
HealthTronics, Inc. and Subsidiaries
Supplemental Financial Information
Continuing Operations
For the Periods Ended December 31, 2009 and 2008
(Unaudited)
(In thousands, except per share data)
Three Months Ended December 31,
Year Ended December 31,
2009
2008
2009
2008
Summary of results from operations
Revenues
$ 50,279
$ 44,637
$ 185,330
$ 165,942
EBITDA(a)
$ 22,667
$ 19,671
$ 82,292
$ 76,263
Adjusted EBITDA(a)
$ 8,524
$ 5,792
$ 26,608
$ 22,004
Net income
$ (2,333)
$ (131,182)
$ (3,916)
$ (128,693)
EPS
$ (0.05)
$ (3.64)
$ (0.10)
$ (3.53)
Number of shares
43,491
36,004
39,135
36,499
Other information:
After tax cash flow(a)
$ 5,018
(b)
(b)
(b)
Net draws (payments) on senior credit facility
$ --
$ 35,000
$ 3,000
$ 41,000
Net debt
$ 40,107
$ 23,533
$ 40,107
$ 23,533
Capital expenditures:
Corporate level
$ 3,309
$ 2,269
$ 4,913
$ 7,942
Partnership level
2,681
748
6,789
3,837
Total
$ 5,990
$ 3,017
$ 11,702
$ 11,779
(a) See accompanying reconciliation of EBITDA, Adjusted
EBITDA, and After Tax Cash Flow.
(b) See accompanying discussion of after tax cash flow.
HealthTronics, Inc. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Continuing Operations
For the Periods Ended December 31, 2009 and 2008
(Unaudited)
(In thousands)
ADJUSTED EBITDA
Three Months Ended December 31,
Year Ended December 31,
Consolidated
2009
2008
2009
2008
Loss from continuing operations
$ (2,333)
$ (131,182)
$ (3,916)
$ (128,693)
Add Back (deduct):
Provision for income taxes
870
(13,246)
2,837
(11,516)
Interest expense
689
486
1,576
1,077
Depreciation and amortization
3,931
3,593
14,544
12,363
Restructuring costs
4,763
1,730
8,649
1,892
Impairment of goodwill
--
144,000
--
144,000
Sharebased compensation costs
604
411
2,918
2,881
Adjusted EBITDA
8,524
5,792
26,608
22,004
Add Back:
Noncontrolling interest expense
14,143
13,879
55,684
54,259
EBITDA
$ 22,667
$ 19,671
$ 82,292
$ 76,263
AFTER TAX CASH FLOW
Three Months Ended
December 31, 2009
Cash provided by operating activities
$ 17,628
Add Back (deduct):
Cash paid for acquisition related costs
536
Distributions to noncontrolling interests
(14,917)
Loan fees
379
Restructuring costs
1,392
After tax cash flow
$ 5,018
NON GAAP NET INCOME
Three Months Ended December 31,
Year Ended December 31,
2009
2008
2009
2008
Income (loss) from continuing operations
$ (2,333)
$ (131,182)
$ (3,916)
$ (128,693)
Add Back (deduct):
Provision for income taxes
870
(13,246)
2,837
(11,516)
Restructuring costs
4,763
1,730
8,649
1,892
Impairment charges
--
144,000
--
144,000
Sharebased compensation costs
604
411
2,918
2,881
3,904
1,713
10,488
8,564
Provision for income taxes at a normalized rate of
38.5%
(1,503)
(660)
(4,038)
(3,297)
Non - GAAP net income
$ 2,401
$ 1,053
$ 6,450
$ 5,267
Non - GAAP net income per share
$ 0.06
$ 0.03
$ 0.16
$ 0.14
EBITDA - Endocare
Three Months Ended
December 31, 2009
Loss from continuing operations - Endocare
$ (659)
Add Back (deduct):
Depreciation and amortization - Endocare
480
Restructuring costs - Endocare
3,117
EBITDA - Endocare
$ 2,938
HealthTronics, Inc. and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
HealthTronics, Inc. Guidance Mid-Point of Range
For the Year Ended December 31, 2010
(Unaudited)
Adjusted EBITDA - HealthTronics Guidance Mid-Point of
Range
Year Ended
December 31, 2010
Income from continuing operations
$ 12,400
Add Back (deduct):
Provision for income taxes
1,600
Interest expense
2,000
Depreciation and amortization
15,000
Sharebased compensation costs
2,000
Adjusted EBITDA
$ 33,000
AFTER TAX CASH FLOW - HealthTronics Guidance Mid-Point of
Range
Year Ended
December 31, 2010
Cash provided by operating activities
$ 80,000
Add Back (deduct):
Distributions to noncontrolling interests
(59,000)
After tax cash flow
$ 21,000
CONTACT: HealthTronics, Inc.
Richard Rusk, Chief Financial Officer
(512) 314-4508
www.healthtronics.com
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024